Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer by Chao, Y et al.
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose
5-fluorouracil and folinic acid in the treatment of advanced gastric
cancer
Y Chao
1, KH Yeh
2,3, CJ Chang
2, LT Chen
1,8, TY Chao
4,M FW u
5, CS Chang
6, JY Chang
2,8, CY Chung
6, WY Kao
4,
RK Hsieh
7 and AL Cheng*,2
1Taipei Veterans General Hospital, Taipei, Taiwan;
2National Taiwan University Hospital, Taipei, Taiwan;
3Far Eastern Memorial Hospital, Taipei, Taiwan;
4Tri-Service General Hospital, Taipei, Taiwan;
5Chung Shan Medical and Dental College Hospital, Taipei, Taiwan;
6Changhua Christian Hospital, Taipei,
Taiwan;
7Mackay Memorial Hospital, Taipei, Taiwan;
8National Health Research Institutes, Taipei, Taiwan
To investigate the efficacy and safety of combining weekly oxaliplatin with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and
folinic acid (FA) in treatment of patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or
recurrent/metastatic gastric cancer were studied. Oxaliplatin 65mgm
 2 2-h intravenous infusion, and 5-FU 2600mgm
 2 plus FA
300mgm
 2 24-h intravenous infusion, were given on days 1 and 8, repeated every 3 weeks. Between January 2001 through January
2002, 55 patients were enrolled. The median age was 64 years (range: 22–75). In all, 52 patients (94.5%) had recurrent or metastatic
disease and three patients had locally advanced disease. Among 50 patients evaluable for tumour response, 28 patients achieved
partial response, with an overall response rate of 56% (95% confidence interval (CI): 41.8–70.3%). All 55 patients were evaluated for
survival and toxicities. Median time to progression and overall survival were 5.2 and 10.0 months, respectively, during median follow-
up time of 24.0 months. Major grades 3–4 toxicities were neutropenia in 23 cycles (7.1%) and thrombocytopenia in 16 cycles (5.0%).
Treatment was discontinued for treatment-related toxicities in nine patients (16.4%), of whom eight were due to oxaliplatin-related
neurotoxicity. One patient (1.8%) died of neutropenic sepsis. This oxaliplatin-containing regimen is effective in the treatment of
advanced gastric cancer. Except for neurotoxicity that often develops after prolonged use of oxaliplatin, the regimen is well tolerated.
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Gastric cancer is the second leading cause of cancer death
worldwide (Ho, 1988; Roder, 2002). The prognosis is generally
poor, with overall 5-year survival ranged from 5 to 15%. Most
patients present with advanced or metastatic diseases, for which
curative resection is not possible. Chemotherapy is used primarily
for palliation of symptoms (Findlay and Cunningham, 1993; Wils,
1996; De Vivo et al, 2000). In the past three decades, a variety of
chemotherapy regimens were developed for the treatment of
advanced gastric cancer (MacDonald et al, 1980; Preusser et al,
1989; Wilke et al, 1990; Wils et al, 1991; Kim et al, 1993; Cocconi
et al, 1994; Zaniboni et al, 1995; Ychou et al, 1996; Cheng et al,
1998). All these regimens had variable degrees of success in phase
II trials; however, results of the subsequent phase III trials often
failed to confirm the relatively high response rates of earlier
reports (Kelsen et al, 1992; Kim et al, 1993; Cocconi et al, 1994;
Webb et al, 1997; Vanhoefer et al, 2000). The survival benefit was
limited with overall survival consistently below 10 months, and
substantial treatment-related toxicities were observed in most
regimens (Waters et al, 1999; Ajani et al, 2003; Ohtsu et al, 2003).
Further, second-line chemotherapy is hardly effective in most
trials, indicating the rapid emergence of drug resistance of gastric
cancer cells to currently available anticancer drugs (Findlay and
Cunningham, 1993; Wils, 1996; De Vivo et al, 2000). New
treatments with better therapeutic index or novel agents with
lesser cross-resistance are needed.
Oxaliplatin is a third-generation platinum compound that has a
wide range of antitumour activities (Machover et al, 1996; Monnet
et al, 1998; de Gramont et al, 2000; Misset et al, 2001). Compared
with cisplatin, oxaliplatin appears to have a better safety profile;
and the cross-resistance to cisplatin is minimal (Kollmannsberger
et al, 2002). Oxaliplatin has higher anticancer activity than
cisplatin in some preclinical experiments (Di Francesco et al,
2002). Synergism between oxaliplatin and 5-fluorouracil (5-FU)
has been demonstrated in vitro (Pendyala and Creaven, 1993; Hsu
et al, 2000), and in vivo (Andre et al, 1999). Combination of
oxaliplatin and 5-FU has proven effective as first- or second-line
treatment for advanced colorectal cancer (Machover et al, 1996; de
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lGramont et al, 2000). Preliminary results of several recent studies
have suggested that various combinations of oxaliplatin and 5-FU
may be as effective in gastric cancer as in colorectal cancer.
We have previously demonstrated that weekly 24-h infusion of
high-dose 5-FU and folinic acid (FA), the HDFL regimen originally
described by Ardalan et al (1991), appears to be particularly useful
in gastric cancer (Yeh and Cheng, 1994; Hsu et al, 1997; Yeh and
Cheng, 1998). We have also provided evidence that prolonged
exposure of gastric cancer cells to low concentration 5-FU for 24h
enhances the inhibition of thymidylate synthase, and thereby
increases the cytotoxicity of 5-FU (Yeh et al, 2000b). Further,
HDFL regimen has repeatedly been demonstrated to cause
minimal myelosuppression (Hsu et al, 1997; Yeh et al, 1997; Yeh
and Cheng, 1998) and is therefore one of the ideal components for
combination chemotherapy with other cytotoxic agents against
gastric cancer. The possible mechanism responsible for the very
low myelotoxicity of HDFL has recently been reported (Yeh et al,
2000a).
This study sought to investigate if combination of oxaliplatin
and HDFL may be a regimen with better therapeutic index for
patients with advanced gastric cancer.
PATIENTS AND METHODS
Patients
Eligibility criteria of the patients included (1) pathologically
confirmed, locally advanced (nonresectable), recurrent or meta-
static gastric cancer, (2) objectively measurable disease by imaging
studies, (3) no prior chemotherapy except postoperative adjuvant
chemotherapy that was received more than 12 months before entry
into the study, (4) ECOG (Eastern Cooperative Oncology Group)
performance status p2, (5) age between 18 and 75 years, (6)
adequate hepatic, renal, and bone marrow functions, and (7)
serum triglyceride 470mgdl
 1. The low limit for serum
triglyceride was set to avoid HDFL-related hyperammonaemic
encephalopathy, which occurs in around 5% of Taiwanese patients
(Yeh and Cheng, 1997).
Exclusion criteria included (1) pre-existing peripheral neuro-
pathy, (2) pregnant, breastfeeding, or woman of child-bearing
potential without adequate contraception, (3) concurrent or prior
malignancy except curatively resected cervical carcinoma in situ or
squamous cell carcinoma of skin, (4) central nervous system
metastases, (5) active infection, and (6) concurrent treatments that
interfered with study evaluation. This study was approved by the
ethics committee of all participating institutes. Signed informed
consent was obtained from all patients.
Study design
This is a prospective, multicentre, phase II clinical trial.
Chemotherapy protocol
On days 1 and 8 of each cycle of chemotherapy, oxaliplatin
65mgm
 2 was given as a 2-h intravenous infusion, then followed
by 5-FU 2600mgm
 2 and FA 300mgm
 2, as a continuous 24-h
intravenous infusion. Treatment was repeated every 21 days.
Treatment was continued until disease progression or unaccep-
table toxicity developed. Patients with complete response received
at least two more cycles of chemotherapy.
Dose modification
Subsequent cycle of chemotherapy was withheld if peripheral
blood neutrophils o1500mm
 3 or platelets o100000mm
 3 was
noted on the due day. If recovery of neutrophils and platelets took
more than 3 weeks after the due day, the patient was removed from
protocol treatment. 5-FU was decreased to 2000mgm
 2 for
subsequent cycles if grade 4 thrombocytopenia or neutropenia
developed in the precedent cycle of chemotherapy. Dose of 5-FU
was further reduced to 1600mgm
 2 for subsequent cycles if grade
4 thrombocytopenia or neutropenia developed again after first
level of dose reduction of 5-FU. Oxaliplatin was decreased to
50mgm
 2 if grade 4 thrombocytopenia or neutropenia developed
after two levels of 5-FU dose reduction. If grade 3–4 nonhaema-
tological toxicities or grade 2 hand–foot syndrome developed,
5-FU was decreased to 2000mgm
 2 for subsequent cycles. Dose of
5-FU was further decreased to 1600mgm
 2 for subsequent cycles
if grade 3–4 nonhaematological toxicities or grade 2 hand–foot
syndrome recurred after first levels of dose reduction of 5-FU.
Oxaliplatin was decreased to 50mgm
 2 if grade 3–4 nonhaema-
tological toxicities or grade 2 hand–foot syndrome developed
again after two levels of 5-FU dose reduction. For grade 2–3
neurotoxicities, oxaliplatin was omitted until recovery of the
neurotoxicities to grade 1 or less; and the dose of oxaliplatin was
decreased to 50mgm
 2 for subsequent cycles. Oxaliplatin was
discontinued if grade 2–3 neurotoxicities lasted for more than 3
weeks.
Evaluation of efficacy and toxicities
Evaluations before chemotherapy included medical history taking,
physical examination, complete blood count, blood chemistry,
chest X-ray, computed tomography (CT) scan of abdomen, and
gastroendoscopy. After starting protocol treatment, complete
blood count was examined weekly and blood chemistry every 3
weeks. Patients’ condition and treatment-related toxicities were
evaluated weekly. Tumour size was measured by imaging studies
every 6 weeks. Tumour response was evaluated according to the
World Health Organization criteria. Toxicities were graded using
the NCI-Common Toxicity Criteria (version 1).
Statistical methods
The Simon two-stage design was used. The response rates of
interest were P0¼40% and P1¼60%. If there were more than 12
responses in 29 patients in the first stage, the study would continue
to 54 patients in the second stage. If there were more than 27
responses in 54 patients in the second stage, this treatment would
be acceptable with a of 0.05 and b of 0.10.
Time to progression was defined as the duration from the date
of starting protocol treatment to the date of documented disease
progression or death by any cause. The overall survival was
defined as the duration from the date of starting protocol
treatment to the date of death. Kaplan–Meier method was used
in all survival analyses.
RESULTS
Patients and treatment
Between January 2001 through January 2002, 55 patients were
enrolled into the study. Major clinicopathologic features of the
patients are listed in Table 1. The median age of the patients was 64
years (range: 22–75). A total of 323 cycles (median: 6, range: 1–17)
of chemotherapy were given. Median relative dose intensity was
95% (range: 67–100%) for oxaliplatin, 95% (range: 48–100%) for
5-FU, and 95% (range: 48–100%) for FA. As oxaliplatin has a
cumulative toxicity, the median relative dose intensity of
oxaliplatin was 100% (range: 70–100%) at cycle 3 and 88% (range:
67–100%) at cycle 6, respectively. In total, 75% of the patients
received more than 80% of intended doses of oxaliplatin, 5-FU
and FA.
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Five patients were not evaluable for response: four failed to return
to the clinic for tumour measurements and one later found to have
nonmeasurable tumours. Of the 50 patients evaluable for tumour
response, there were 28 patients with partial remission (PR), four
patients with stable disease (SD), and 18 patients with progressive
disease (PD). The total tumour response rate was 56% (95% CI:
41.8–70.3%). The median time to tumour response was 3 months
(range: 2.2–8.3 months). Five out of the six patients, who had
previously received postoperative adjuvant chemotherapy which
contains cisplatin and 5-FU, achieved PR. Two responders went on
to receive curative surgical resection or radiotherapy for the
residual tumours. Both patients were alive and tumour-free at 16
and 25 months after starting protocol chemotherapy, respectively.
Median follow-up time of the whole group of 55 patients was
24.0 months as cut-off date for analysis on 25 July 2003. The
median time to progression was 5.2 months (95% CI: 4.0–7.0
months) (Figure 1). The median overall survival was 10.0 months
(95% CI: 8.0–13.3 months) (Figure 2).
Toxicity
All 55 patients were evaluated for toxicities (Table 2). Nine patients
(14.5%) discontinued treatment because of treatment-related
toxicity. Eight out of these nine patients discontinued treatment
because of oxaliplatin-related neurotoxicity. The median dose of
oxaliplatin received by these eight patients was 910mgm
 2 (range:
715–1170mgm
 2). Another patient discontinued treatment due to
heart failure, which was considered unrelated to chemotherapy.
Table 1 Clinicopathologic features of the patients
Patient number (%)
Total patients 55
Sex: male/female 36/19
ECOG performance
0 9 (16.4)
1 39 (70.9)
2 7 (12.7)
Treatments for primary tumour
No prior therapy 31 (56.4)
Surgery only 18 (32.7)
Surgery + adjuvant chemotherapy 6 (10.9)
Disease status
Locally advanced 3 (5.5)
Recurrence/metastasis 52 (94.6%)
Disease sites
Liver 26 (47.3)
Lymph nodes 28 (50.9)
Peritoneum 15 (27.3)
Gastrointestinal tract 9 (16.4)
Bone 9 (16.4)
Lung 5 (9.1)
Others 11 (20)
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Figure 1 Time to progression of the 55 patients.
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Figure 2 Overall survival of the 55 patients.
Table 2 Toxicity of the oxaliplatin-HDFL regimen
Patients (n¼55) Cycles (n¼323)
Grade Grade Grade Grade
Toxicity 1–2 3–4 1–2 3–4
Haematological
Neutropenia 72.7
a 21.8 34.3
b 7.1
Leukopenia 58.1 7.2 21.0 1.8
Thrombocytopenia 60.0 12.7 24.5 5.0
Febrile neutropenia 1.8 5.4 0.3 0.9
Anaemia 61.8 9.0 34.7 2.8
Gastrointestinal
Nausea 81.8 10.9 38.4 2.5
Vomiting 87.2 12.7 31.6 2.2
Diarrhoea 69.1 12.7 22.0 2.4
Stomatitis 50.9 3.6 13.3 0.9
Anorexia 70.9 1.8 36.5 0.3
Weight loss 9.1 0 1.85 0
Neuropathic 72.7 12.7 46.8 2.2
Others
Cardiac 0 1.8 0 0.3
Fever 27.3 1.8 7.1 0.3
Infection without neutropenia 16.4 0 4.3 0
Alopecia 21.8 0 16.4 0
aAll numbers are percentage of the 55 patients.
bAll numbers are percentage of the
323 cycles given.
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The results of this phase II study indicated that weekly oxaliplatin
and 24-h infusion of high-dose 5-FU and FA is an effective
combination chemotherapy for advanced gastric cancer. The
overall response rate of 56% was within the range (30–70%) of
previous major protocols such as FAMTX, ELF, EAP, ECF, and
recent taxane-based (Bokemeyer et al, 1997; Kollmannsberger
et al, 2000; Cascinu et al, 2001) or irinotecan-based regimens
(Bleiberg, 1999; Ajani et al, 2002; Slater et al, 2002). Recently,
three other studies, using different administrating schedules of
oxaliplatin and 5-FU, have also demonstrated a good efficacy
in gastric cancer (Louvet et al, 2002; Kim et al, 2003; Al-Batran
et al, 2004). These phase II studies showed a response rates of
43–44.9% (Louvet et al, 2002; Al-Batran et al, 2004) and 26%
(Kim et al, 2003) in the first- and second-line treatment,
respectively. Oxaliplatin appears to be a useful adjunct to systemic
chemotherapy against advanced gastric cancer. Currently, a
randomised multicentre study (REAL-2) is underway with a two
by two factorial design to compare the efficacy of capecitabine
with 5-FU, and oxaliplatin with cisplatin in the ECF regimen,
for patients with advanced oesophagogastric cancer. The study
aims to enroll 1000 patients with the primary end point being
1-year survival. The interim analysis of the REAL-2 study
showed good antitumour activity in favour of oxaliplatin and
capecitabine with a response rate of 52% (95% CI: 34.4–68.1%) in
an EOX (epirubicin, oxaliplatin, capecitabine) regimen (Sumpter
et al, 2003).
In this study, 5-FU and FA was given by two weekly 24-h
infusion (the HDFL regimen) every 3 weeks. The rationale of
this scheduling for 5-FU was based on our previous observations
which indicated that HDFL is in general a highly effective and
very safe regimen for advanced gastric cancer (Hsu et al, 1997; Yeh
and Cheng, 1998). The patients’ compliance was excellent. To
avoid calcite precipitation and catheter blockage (Ardalan et al,
1991, 1995), we decreased the dose of FA from 500 to 300mgm
 2,
mixed the high-dose 5-FU and FA in the same infusion bag,
and administered via an ambulatory infusion pump (Yeh and
Cheng, 1994). This effective, nonmyelosuppressive, convenient
outpatient-based administration of HDFL has been widely used at
many institutions in Taiwan since 1994 (Yeh and Cheng, 1994),
instead of much more complicated administration of LV5FU2
regimen (de Gramont regimen) in FOLFOX combination (de
Gramont et al, 2000). A phase II study of high-dose 5-FU
(2600mgm
 2) and FA (500mgm
 2), German AIO regimen, has
also been reported as a salvage regimen in gastric cancer with
partial remissions of 18% and stable disease of 41% (Vanhoefer
et al, 1994). The decreased dose of FA (300mgm
 2) in our HDFL
compared to German AIO regimen may also decrease the toxicity
of grade 3/4 diarrhoea (Kohne et al, 2003). Further, results of our
in vitro studies have implied that strict avoidance of bolus
injection of 5-FU is the key to avoid myelosuppression (Yeh et al,
2000a). Although the best protocol of 5-FU remains to be explored
(Johnson et al, 1991; Louvet et al, 1991), both clinical and
laboratory data indicate that HDFL is one of the ideal components
for combination chemotherapy with other cytotoxic agents against
gastric cancer.
In this study, five out of six patients who had received prior
adjuvant chemotherapy which contains cisplatin and 5-FU
responded to the current protocol. A similar observation has
recently been reported by Kim et al (2003). It appears that
oxaliplatin has no significant cross-resistance with cisplatin in
gastric cancer. Therefore, it is intriguing to examine if oxaliplatin
is effective in second-line chemotherapy for gastric cancer patients
recurrent from cisplatin-containing regimens.
Although survival is not a reliable end point for evaluation of
efficacy in phase II trials, the median overall survival of 10.0
months in this study compared favourably to ECF (8.7 months),
FAMTX (6.1 months), FAMTX (6.7 months), ELF (7.2 months),
FUP (7.2 months), and FOLFOX 6 (8.6 months) (Webb et al, 1997;
Vanhoefer et al, 2000; Louvet et al, 2002). It also compares
favourably to prior studies conducted in our institutions on
similar groups of patients (Hsu et al, 1997; Cheng et al, 1998; Chi
et al, 1998).
Except for the oxaliplatin-related neurotoxicity (Cassidy and
Misset, 2002), the current oxaliplatin-HDFL protocol is generally
well tolerated. Neurotoxicity was also found to be the predominant
dose-limiting toxicity in another oxaliplatin-containing regimen
for gastric cancer (Louvet et al, 2002). Other major toxicities,
including neutropenia, thrombocytopenia, stomatitis, and diar-
rhoea, were of the same range of severity as other major regimens
such as FAMTX, ECF, FUP, ELF, and FOLFOX6 (Webb et al, 1997;
Vanhoefer et al, 2000; Louvet et al, 2002). Owing to patients’
selection in phase II studies, it may not be possible or relevant to
compare the toxicity profiles of the present study with three other
phase II studies, using different administrating schedules of
oxaliplatin and 5-FU in gastric cancer (Louvet et al, 2002; Kim
et al, 2003; Al-Batran et al, 2004). However, the haematological
toxicity of the present study is still favourable and well tolerated
with grade 3–4 neutropenia and febrile neutropenia of 7.1 and
0.9%, respectively, in a total of 323 cycles given. Further, the
absence of grade-2 alopecia in this study compared favourably to
other regimens.
We conclude that combination of weekly oxaliplatin and weekly
24-h infusion of 5-FU and FA is an active regimen with acceptable
toxicities for the treatment of advanced gastric cancer.
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